000			01709 a2200469 4500
005			20250515182659.0
264		0	_c20090827
008			200908s 0 0 eng d
022			_a1941-9260
024	7		_a10.3810/pgm.5.15.2000.suppl4.23 _2doi
040			_aNLM _beng _cNLM
100	1		_aDavis, S N
245	0	0	_aAdvances in oral therapy for type 2 diabetes. _h[electronic resource]
260			_bPostgraduate medicine _cMay 2000
300			_a16-20 p. _bdigital
500			_aPublication Type: Journal Article; Review
650	0	4	_aAcarbose _xtherapeutic use
650	0	4	_aAdministration, Oral
650	0	4	_aBlood Glucose _xdrug effects
650	0	4	_aCarbamates _xtherapeutic use
650	0	4	_aCyclohexanes _xtherapeutic use
650	0	4	_aDiabetes Mellitus, Type 2 _xdrug therapy
650	0	4	_aDrug Combinations
650	0	4	_aDrug Therapy, Combination
650	0	4	_aGlycated Hemoglobin _xdrug effects
650	0	4	_aHumans
650	0	4	_aHypoglycemia _xchemically induced
650	0	4	_aHypoglycemic Agents _xadverse effects
650	0	4	_aInsulin _xmetabolism
650	0	4	_aInsulin Secretion
650	0	4	_aInsulin-Secreting Cells _xdrug effects
650	0	4	_aMetformin _xtherapeutic use
650	0	4	_aNateglinide
650	0	4	_aPhenylalanine _xanalogs & derivatives
650	0	4	_aPiperidines _xtherapeutic use
650	0	4	_aRandomized Controlled Trials as Topic
650	0	4	_aThiazolidinediones _xtherapeutic use
650	0	4	_aUnited States _xepidemiology
650	0	4	_aWeight Gain _xdrug effects
773	0		_tPostgraduate medicine _gvol. 107 _gno. 6 Suppl Key _gp. 16-20
856	4	0	_uhttps://doi.org/10.3810/pgm.5.15.2000.suppl4.23 _zAvailable from publisher's website
999			_c19073815 _d19073815